Back to Search
Start Over
Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies.
- Source :
-
Cancer cell [Cancer Cell] 2022 Jun 13; Vol. 40 (6), pp. 590-591. Date of Electronic Publication: 2022 May 16. - Publication Year :
- 2022
-
Abstract
- Competing Interests: Declaration of interests The authors report no competing interests related to the research. S.A.V. is an advisor for Immunai and previously consulted for ADC Therapeutics and Koch Disruptive Technologies. A.N. is an advisor for Janssen, Morphosys, and Epizyme, has consulted for Physician Education Resource, has received honoraria from Medscape and Pharmacyclics, and has received research funding from Pharmacyclics and Rafael Pharmaceuticals.
Details
- Language :
- English
- ISSN :
- 1878-3686
- Volume :
- 40
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- Cancer cell
- Publication Type :
- Report
- Accession number :
- 35598602
- Full Text :
- https://doi.org/10.1016/j.ccell.2022.05.007